Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 13INDUSTRY 6NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Liver Neoplasms 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Diabetes Mellitus, Insulin-Dependent, 12 1Cholangiocarcinoma 1Bile Duct Neoplasms 1

Interventions

Cyclophosphamide 109Bevacizumab 97Magnetic Resonance Spectroscopy 91Specimen Handling 88Biopsy 75Paclitaxel 64fludarabine phosphate 62Immunoglobulin G 61Disulfides 61Carboplatin 58Taxes 53Cisplatin 52Doxorubicin 51fludarabine 49Sorafenib 46Radiation 46aldesleukin 45Radiotherapy 45Prednisone 45Etoposide 45Vincristine 41Sirolimus 40Platinum 40Bortezomib 38Rituximab 371,2-diaminocyclohexaneplatinum II citrate 37Nivolumab 36Cytarabine 35temsirolimus 34Vorinostat 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Has results × Cryosurgery × Clear all
NCT02821754 2023-03-28

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
54 enrolled 14 charts
Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Cholangiocarcinoma

NCT01853618 2019-12-10

Tremelimumab With Chemoembolization or Ablation for Liver Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
61 enrolled 18 charts
Gastrointestinal

Biliary Tract Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡